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ABSTRACT 
Colorectal cancer mortality largely reflects metastasis, the spread of the disease at distant 
organs.  Matrix metalloproteinase 9 is a key regulator of metastasis and a target for 
anticancer strategies in colon cancer.  Here, overexpression of matrix metalloproteinase 9 
in pure tumor epithelial, but nor stromal, cell populations was associated with metastatic 
progression of colorectal cancer as defined by RT-PCR and confirmed by 
immunostaining.  Thus, cancer cell matrix metalloproteinase 9 represents a novel, 
selective prognostic and predictive factor that may be exploited for more effective disease 
stage stratification and therapeutic regimen selection in patients with colorectal cancer. 
INTRODUCTION 
Prevention or interruption of metastatic disease progression represents an unfilled 
therapeutic gap in the management of patients with colorectal cancer, the second leading 
cause of tumor-related mortality in developed nations.
1,2
  Metastasis results from 
dissemination of select cell clones, exhibiting aberrant migratory and survival abilities, 
from the primary tumor to distant organs where they establish extra-intestinal colonies 
and remodel the local parenchyma.
3,4
  Uniformly, this process drastically aggravates the 
patient outlook and less than 10% of patients with colon cancer metastasis at distant 
organs survive beyond five year from diagnosis.
1
  Effective strategies to reduce mortality 
and improve patient outcomes include early detection of pre-metastatic disease and 
timely recognition of metastatic spread.
2
  However, reliable pathological markers of 
metastatic colorectal cancer are scarce, reflected by the genotypic and phenotypic 
heterogeneity of colon cancer cells and the variability in analytical methods employed.
3-5
  
Moreover, despite the progress of current chemotherapeutic regimens, advanced 
colorectal cancer with distant metastatic deposits remains incurable.
6-8
  Thus, 
identification of novel, selective prognostic indicators and therapeutic targets of 
metastatic disease progression are of paramount importance to reduce morbidity and 
mortality from colorectal cancer. 
Matrix metalloproteinases (MMPs) are zinc-dependent metalloendopeptidases which 
mediate metastasis.
9,10
  Cancer cells employ MMPs to cleave the extracellular matrix and 
invade surrounding tissues.
10,11
  Specifically, in colon cancer MMP-9 has emerged as a 
critical pro-metastatic protease regulating tumor cell growth, mobility and survival.
8,11,12
  
A complex interplay between MMP-9 activity, dynamic membrane regions and signaling 
by adhesion molecules regulates tumor cell migration, invasion and metastasis.
13-15
  
Further, MMP-9 promotes tumor neovascularization by specifically activating angiogenic 
factors at the cancer cell/matrix interface.
16
  Consistent with the hypothesis that MMP-9 
is a key regulator of the malignant phenotype, colorectal tumors from patients exhibit 
overexpression of MMP-9 compared to matched normal adjacent tissues.
8,12
  In that 
context, stromal cells within the primary colorectal tumor are principal MMP-9 producers 
and may promote invasion and metastasis by cancer cells.
17,18
  However, human 
colorectal cancer cells also exhibit cell autonomous abilities to synthesize and secrete 
MMP-9, an effect associated with induction of MMP-9-dependent proteolytic functions 
at the pericellular space which mediate metastasis.
8
  Indeed, tumor epithelial cell MMP-9 
promotes extracellular matrix degradation, actin polymerization-driven cell spreading, 
and hematogenous tumor cell seeding of mouse lungs.
8
 
In principle, tumor epithelial cell MMP-9 may represent a specific diagnostic and 
therapeutic target for colorectal cancer metastasis.
8
  Obstacles to these clinical 
applications include the unknown prognostic role of cancer cell MMP-9, the contribution 
of stroma-derived MMP-9 to cancer cell pathobiology, and the absence of approaches 
that selectively target MMP-9 functions mediating metastasis.  Here, a previously 
unrecognized potential for colon tumor epithelial cell MMP-9 as a specific and selective 
biomarker of metastatic disease progression is revealed.  Specifically, relative increase of 
MMP-9 expression in tumor intestinal epithelial, but not stromal, cells compared to 
matched normal mucosa cells was demonstrated to predict locoregional metastatic 
propagation and correlate with advanced disease stages.  Together, these observations 
suggest MMP-9 in tumor epithelial cells is a novel prognostic and predictive marker and 
a potential therapeutic target for patients with colorectal cancer. 
METHODS 
Clinical specimens 
Fresh surgical specimens from 11 patients (Table I) with histologically-confirmed 
adenocarcinomas of the colo-rectum were obtained from the Department of Pathology, 
Anatomy and Cell Biology of Thomas Jefferson University (Philadelphia, PA) under a 
protocol approved by the Institutional Review Board. 
Isolation of pure intestinal cell populations 
Colorectal tumors and normal adjacent tissues were subjected to proteolytic digestion by 
incubation (37°C for 1 h) in L-15 media containing 10% FBS, 0.1 μg/ml insulin, 50 
ng/ml EGF, 2 mM L-glutamine, 100 μ/ml penicillin and streptomycin, 125 μg/ml 
fungizone and 1,250 units/ml collagenase XI.  Following digestion, dissociated intestinal 
cells were passed through a cell strainer, magnetically labeled with magnetic microbeads 
conjugated to a mouse antibody directed against the human epithelial antigen (HEA), and 
transferred into a magnetic activated cell sorting (MACS) column (Miltenyi
 
Biotec, 
Germany).  After washing to recover the unlabeled fraction, which includes stromal cells, 
magnetically-retained HEA
+
 cells were removed from the magnetic field and collected 
with MACS elution buffer.  To further purify intestinal epithelial cells from residual cell 
contamination, MACS-sorted HEA
+
 cells were fluorescently labeled by incubation with 
PE-conjugated mouse anti-human CD104 (BD Biosciences, San Jose, CA), another 
specific intestinal epithelial cell marker, and subjected to fluorescent activated cell 
sorting (FACS) employing a FACS Caliber flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ).  The MACS flow-through (unlabeled fraction) was also subjected to FACS 
employing FITC-conjugated anti-CD45 (Miltenyi
 
Biotec, Germany), a stromal cell 
marker, to obtain purified intestinal stromal cells. 
Real-time reverse transcription-PCR 
Purified cell populations from patients were pelleted and resuspended in RNAlater 
(Ambion, Inc., Austin, TX).  Total RNA was isolated with the Qiagen RNA Easy kit 
(Qiagen, Valencia, CA) and subjected to one-step reverse transcription (RT)-PCR on a 
7000 Sequence Detection System for 45 cycles (95°C, 5 minutes; 94°C, 20 minutes; 
62°C, 1 minute) using Taqman® EZ RT-PCR Core Reagents (Applied Biosystems, Inc., 
Foster City, California).  MMP-9 and β-actin mRNAs were specifically detected and 
quantified with respective fluorescently labeled primers/probe sets (Assay on Demand, 
Applied Biosystems).  Data were analyzed using Sequence Detection Software (Applied 
Biosystems) with thresholds set at 0.2.  Template-negative controls were run on each 
PCR plate. 
Immunostaining 
Paraffin-embedded intestinal sections (5 μm) from clinical specimens were 
deparaffinized and rehydrated with sequential washes of xylene, ethanol and water.  
Antigens were unmasked by heating twice at 100°C for 5 min in 10 mM citric buffer, pH 
6.0.  For immunohistochemistry (IHC), tissue sections were incubated overnight at 4°C 
with a goat polyclonal antibody against human MMP-9 (R&D Systems, Minneapolis, 
MN; 20 μg/ml), followed by incubation with the secondary antibody and DAB substrate 
(Avidin-biotin kit; Vector Laboratory, Burlingame, CA).  For immunofluorescence, 
tissue slides were first incubated overnight at room temperature with the goat polyclonal 
antibody against human MMP-9 (R&D Systems; 20 μg/ml) or the rabbit polyclonal 
antibody against human β-catenin (Santa Cruz, Santa Cruz, CA; 1:50).  Then, the specific 
primary antibody binding was visualized employing AlexaFluor 555 conjugated donkey 
anti-goat or AlexaFluor 488 conjugated donkey anti-rabbit secondary antibodies 
(Molecular Probes, Eugene, OR).  Sections were counterstained with Slowfade Gold 
antifade reagent with DAPI (Molecular Probes) to identify individual cells and nuclei and 
examined with a Zeiss LSM 510 Meta Confocal microscope.  Secondary antibody alone 
was used as negative control. 
Statistical analysis 
Unless otherwise indicated, data were expressed as the mean ± SEM.  The association 
between patient sub-groups with relative stromal or epithelial MMP-9 overexpression and 
the degree of lymph node involvement was evaluated employing the exact version of 
Cochran-Armitage Trend test.  Differences in stage grouping scores and percent of 
positive nodes between patients with increased and decreased MMP-9 mRNA levels in 
tumor cell populations were determined by Wilcoxon two-sample test.  Data were 
analyzed employing StatExact 7 (Sytel Software Corporation, Cambridge, MA). 
RESULTS 
Increased MMP-9 expression in colorectal tumor cells is associated with 
locoregional metastatic dissemination 
Normal adjacent intestinal mucosa and colorectal tumors from 11 patients were subjected 
to collagenase digestion.  Crude populations enriched in epithelial or stromal cells were 
first obtained by isolating cells positive and negative for HEA from the bulk of 
dissociated human intestinal cells employing MACS sorting.  Purified intestinal epithelial 
(Figure 1, top panels) and stromal (Figure 1, bottom panels) cells were collected 
employing FACS sorting with PE-conjugated anti-CD104 (on MACS-isolated HEA
+
 
cells) and FITC-conjugated anti-CD45 (on unlabeled cells of the MACS flow-through), 
respectively.  Then, isolated epithelial and stromal cells were subjected to real-time RT-
PCR for quantification of MMP-9 mRNA.  MMP-9 was expressed in all epithelial and 
stromal cells from patients examined (Figure 2A).  Further, within epithelial or stromal 
cell populations, MMP-9 expression was increased or decreased in cells purified from 
tumors compared to matched normal adjacent tissues (Figure 2A).  Importantly, local 
metastasis to regional lymph nodes occurred only in patients exhibiting increased MMP-9 
expression in tumor cells (Figure 2B).  In contrast, all cancer patients with decreased 
MMP-9 levels in both epithelial and stromal cells from tumors were node-negative 
(Figure 2B). 
MMP-9 in tumor epithelial cells is a prognostic indicator of metastatic colorectal 
cancer 
Of significance, 100% of patients (n=5) with relative MMP-9 overexpression in tumor 
epithelial cells, compared to normal epithelial cells, exhibited lymph node involvement.  
Among the different pathologic sub-groups defined by the relative MMP-9 expression in 
tumors, colorectal cancer patients with tumor epithelial cell MMP-9 overexpression 
exhibited the highest metastatic tumor burden in regional lymph nodes (Figure 2B).  
Conversely, only 83% of patients (n=6) with relative MMP-9 overexpression in tumor 
stromal cells, compared to stromal cells from the adjacent normal mucosa, had node-
positive disease, reflected by low-to-intermediate metastatic involvement (Figure 2B).  
Accordingly, the proportion of patients with relative overexpression of MMP-9 in tumor 
epithelial, but not stromal, cells increased significantly in higher node-positive stages 
(N0, 0%; N1, 50%; N2, 100%), as defined employing the tumor node metastasis (TNM) 
system by the American Joint Committee on Cancer (AJCC) (Figure 3, left panels).
19
  
Attribution of an arbitrary score to the TNM-based stage grouping of patients examined 
(Table II) revealed that patients with increased MMP-9 levels in tumor epithelial cells 
exhibited the most advanced stage of disease, which was significantly higher than that of 
patients (n=6) with decreased MMP-9 expression in cancer cell populations (stage score: 
6.60 ± 0.27 in patients with increased cancer cell MMP-9 vs 3.83 ± 0.77 in patients with 
decreased cancer cell MMP-9, p=0.022; Figure 3, bottom-middle panel).  No significant 
difference in stage grouping scores was detected between patients with relative MMP-9 
overexpression in tumor stromal cells and those with relative MMP-9 downregulation in 
the same cell population (Figure 3, upper-middle panel).  Further, patients with a relative 
increase in expression of MMP-9 mRNA in epithelial cells in tumors, compared to 
matched normal tissues, exhibited a significantly higher proportion of regional lymph 
nodes harboring metastases than patients with a relative decrease in MMP-9 expression 
(percent of lymph node-positive: 27.20 ± 9.60 in patients with increased cancer cell 
MMP-9 vs 4.85 ± 4.00 in patients with decreased cancer cell MMP-9, p=0.017; Figure 3, 
bottom-right panel).  In contrast, disease burden in patients did not correlate with relative 
changes in MMP-9 expression in tumor stromal cells compared to normal adjacent tissues 
(Figure 3, upper-right panel). 
Overexpression of MMP-9 in colon tumor cell compartments is detected by 
conventional histopathology 
Paraffin-embedded tissue slides from patients with colorectal cancer were immunostained 
for MMP-9 (Figure 4).  IHC analysis revealed that MMP-9 protein is detected in both 
normal adjacent tissues and primary tumors from colon cancer patients (Figure 4, left 
panels).  Moreover, confocal microscopy of tissue specimens from a patient with node-
positive disease demonstrated overexpression of MMP-9 protein in primary tumor cell 
compartments, compared to cells from the matched normal adjacent mucosa (Figure 4, 
right panels).  Importantly, MMP-9 in tumor epithelial cells was specifically identified by 
co-localization of immunofluorescent signals from MMP-9 and β-catenin (Figure 4, right 
panels).  These analyses revealed that increased MMP-9 protein in colon epithelial cell 
populations of the primary tumor can be detected by routine histopathological techniques 
(Figure 4, right panels). 
DISCUSSION 
The mortality rate for large bowel cancer, ~50%, largely reflects metastatic disease 
progression, and tumor deposits at distant locations signify unresectable and untreatable 
disease.
1,19
  Although the final stages are irreversible, formation of metastatic foci of 
colon cancer cells at extra-intestinal sites is a vulnerable, multi-step process.  Thus, for 
hematogenous metastatic dissemination cancer cells have to detach from surrounding 
stroma, migrate through tissue boundaries and invade the primary organ, intravasate into 
blood vessels, embolize and distribute to distant tissues.
4
  Following tumor seeding, only 
select cancer cells with unique abilities to engage productive cell-matrix interactions with 
the host parenchyma proliferate and form the metastatic niche.
3,20
  Further, to establish 
enduring metastasis colon cancer cells have to evade local immune anti-tumor defenses, 
maliciously remodel the host micro-environment, and develop an autonomous vascular 
network.
4,21
  As a result, metastasis is a highly selective and inefficient process and 
>99.99% of intravasated tumor cells are eliminated before reaching their final 
destination.
22
  The complexity of the metastatic process, and its attendant rate-limitation 
associated with disruption of any individual step, is at the basis of the efficacy of 
postsurgical adjuvant chemotherapy to prolong survival and reduce mortality in patients 
with early metastatic colorectal cancer, as determined by lymph node involvement in the 
absence of distant metastases.
23
 
Current pathologic assessment of regional colorectal cancer metastasis is performed by 
examining mesenteric nodes in surgical colectomy specimens with traditional 
hematoxylin-eosin staining.
24
  However, accuracy in estimating node tumor burden is 
hampered by the great variability in nodal harvest, as a result of interpatient anatomic 
differences, extent of surgical lymphadenectomy and the ability to search for lymph 
nodes by the pathologist.
25
  The unclear number of lymph nodes to analyze and the 
imperfect sensitivity of histopathology represent other obstacles for appropriate 
metastatic disease evaluation.
24,25
  Although introduction of newer molecular-based 
methods of diagnosis selective for the metastatic process has been invoked,
5
 specific 
biological markers of colorectal cancer metastasis have not emerged.  Here, node-positive 
disease always was associated with increased MMP-9 expression in tumor cell 
compartments compared to matched normal mucosa cells, indicating that relative 
increase of MMP-9 expression in colorectal tumor cells is a specific biomarker of 
metastatic dissemination.  Importantly, MMP-9 overexpression in cells of the primary 
tumors could be detected by both RT-PCR and standard IHC techniques.  The 
implications of these findings on patient management are important, because they suggest 
that pathological analysis of the primary tumor, regardless of lymph node status, may be 
sufficient for detecting early colorectal cancer metastasis. 
Pathologic staging of patients remains the most important prognostic factor for colorectal 
cancer.
7
  Indeed, the survival rate of these patients is inversely correlated with the 
AJCC/TNM stage (Table II), and while more than 90% of patients with stage I survive 5 
years from the initial diagnosis, less than 60% or 10% of them are still alive when 
metastasis has spread to regional (stage III) or distant (stage IV) locations, 
respectively.
1,19
  There is a considerable risk to understage patients with current 
histological methods of pathologic node evaluation.
5,25
  Specifically, a clear prognostic 
dis-homogeneity exists for the node-positive stage III group, and various permutations of 
the N category have been proposed to better stratify colorectal cancer patients with lymph 
node involvement.
24
  Here, relative MMP-9 overexpression in tumor epithelial cells, 
compared to normal epithelial cells, predicted lymph node involvement and correlated 
with increased metastatic tumor burden.  Importantly, the patient population exhibiting 
relative increase of tumor epithelial cell MMP-9 was significantly enriched in higher 
node-positive stages, suggesting that cancer cell MMP-9 overexpression is a novel 
prognostic factor in colon cancer.  Moreover, colorectal cancer group staging is the 
fundamental predictive factor for patient management.  Thus, pre-metastatic disease 
stages often require surgery alone with curative outcomes, while metastatic stages 
warrant postsurgical adjuvant chemotherapy with the intent to improve expectancy and 
quality of life.
6,7
  Careful stratification of node-positive stage III groups, in turn, may 
represent the key discriminator for directing patients to less (for stage IIIA), intermediate 
(for stage IIIB) or more (for stage IIIC) aggressive therapeutic regimens.
24
  Patients with 
relative increase of MMP-9 levels in tumor epithelial cells signified advanced disease 
stages, characterized by significantly higher proportion of regional lymph nodes 
harboring metastasis compared to patients with a relative decrease in MMP-9 expression.  
Thus, MMP-9 overexpression in primary tumor epithelial cells may represent a highly 
specific molecular marker for both the prognostic and predictive stratification of patients 
with colorectal cancer. 
In colorectal tumors, fibroblasts and inflammatory cells of the stromal compartment are a 
principal source of MMP-9, which may confer metastatic abilities to neighboring cancer 
cells.
17,18
  However, examination of pure cell populations from tumors and adjacent 
normal mucosa of patients with colorectal cancer demonstrated that MMP-9 of epithelial, 
but not stromal, cells functions as a pathological marker of metastatic disease 
progression.  Accordingly, cancer cell MMP-9 is a critical regulator of the pathobiology 
underlying colorectal metastasis, selectively promoting migration, invasion and seeding 
of target organs by tumor cells.
8
  Thus beyond stromal cell contribution, MMP-9 
produced by tumor epithelial cells may control unique cellular functions mediating 
metastasis.  Precise elucidations of these mechanisms underlying colorectal cancer 
invasion and metastasis may provide novel, highly selective and effective therapeutic 
strategies for targeted prevention and treatment of colorectal cancer metastasis. 
CONCLUSION 
Advanced, metastatic colorectal cancer remains incurable.  Accurate patient stratification 
into defined prognostic and predictive disease stages is essential to improve quality of 
life, prolong survival and reduce mortality in colorectal cancer.
5,7,25
  MMP-9 
overexpression in tumor epithelial cells is a novel, specific and selective marker for the 
prognosis and management of patients with colorectal cancer.  Further, cancer cell MMP-
9 represents a novel predictive factor which may indicate treatment response and targeted 
therapy selection to prevent and treat metastatic disease progression.  If future studies 
will demonstrate that MMP-9 overexpression in cancer cells is an independent prognostic 
and predictive factor, translation of these previously undescribed MMP-9 functions into 
clinical practice have the potential to profoundly impact the management and cure of 
patients with colorectal cancer. 
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Table I.  Clinicopathologic Parameters of Colorectal Cancer Patients 
Age (y)    
 Median (range) 61 (54-85) 
 
Gender (%)    
 Male  7 (63.6) 
 Female  4 (36.3) 
 
Tumor Site (%)   
 Colon  10 (90.9) 
 Rectum  1 (9.1) 
 
Dukes' Tumor Stage (%)  
 A  1 (9.1) 
 B  3 (27.2) 
 C  5 (45.5) 
 D  2 (18.2) 
 
Differentiation Grade (%)  
 Well  1 (9.1) 
 Moderate 7 (63.6) 
 Poor  3 (27.2) 
 
Tumor Depth* (%)   
 Tis  0 (0) 
 T1  0 (0) 
 T2  1 (9.1) 
 T3  9 (81.8) 
 T4  1 (9.1) 
 
Lymph Node Metastasis (%)  
 Yes  7 (63.6) 
 No  4 (36.3) 
 
Distant Metastasis (%)  
 Yes  2 (18.2) 
 Not determined  9 (81.8) 
 
*Tis, limited to mucosa (carcinoma in situ); T1, limited to submucosa; 
T2, invading the muscularis propria; T3, invading the serosa; T4, invading 
adjacent organs.
Table II.  TNM-Based Stage Group and Score for Colorectal Cancer Patients 
Stage Group TNM* Lymph Nodes 
Examined 
(Range) 
Patient 
Number (%) 
Score 
0 Tis, N0, M0 0 0 (0) 1 
I T1-2, N0, M0 27 1 (9.1) 2 
IIA T3, N0, M0 13-23 3 (27.3) 3 
IIB T4, N0, M0 0 0 (0) 4 
IIIA T1-2, N1, M0 0 0 (0) 5 
IIIB T3-4, N1, M0 9-29 4 (36.3) 6 
IIIC T1-4, N2, M0 13-33 3 (27.3) 7 
IV
+
 T1-4, N0-2, M1 0 0 8 
*T categories are as described in Table 1; N0, no lymph nodes involvement; N1, 
metastasis in 1-3 lymph nodes; N2, metastasis in ≥4 lymph nodes; M0, no distant 
metastasis; M1, metastasis at distant organs. 
+
No patients were included in the stage IV group because almost universally the M 
category was not determined (Table I). 
 
FIGURE LEGENDS 
Figure 1.  Isolation of pure epithelial and stromal cell populations from primary 
tumors and matched normal mucosa of patients with colorectal cancer.  Following 
collagenase digestion and MACS-sorting, epithelial (MACS elution) or stromal (MACS 
flow-through) cells of normal adjacent tissue (NAT) and colorectal tumors (Tumor) 
isolated from patients were subjected to FACS-sorting.  Pure intestinal epithelial (red box 
for PE-conjugated anti-CD104) or stromal (green box for FITC-conjugated anti-CD45) 
cell populations were collected for further analysis. 
Figure 2.  Relative MMP-9 expression levels in colorectal tumor cell populations 
exhibit prognostic significance.  (A) Stromal and epithelial cells from primary colorectal 
tumors (Tumor) and normal adjacent tissue (NAT) isolated by MACS- and FACS-sorting 
were subjected to RT-PCR.  Sample levels of MMP-9 mRNA were normalized to 
respective β-actin mRNA using the formula 2[(MMP-9 Ct) –(β-actin Ct)], where Ct is the sample 
threshold cycle number.  Lines connect data from matched specimens from the same 
patient.  Box plots, median and values from the 25
th
-75
th
 percentile; whiskers, range of 
values.  (B) Lymph nodes involvement in the different sub-groups of patients as defined 
by the relative expression of tumor cell MMP-9 compared to the matched normal mucosa 
cell MMP-9.  ↑MMP-9, MMP-9 overexpression; ↓MMP-9, MMP-9 downregulation; E, 
tumor epithelial cells; S, tumor stromal cells. 
Figure 3.  MMP-9 overexpression in tumor epithelial cells is a biological marker of 
colorectal cancer metastasis.  Association between MMP-9 overexpression in tumor 
cell populations and lymph node involvement (left panels).  Compared to those with 
tumor MMP-9 downregulation, patients with MMP-9 overexpression in tumor epithelial, 
but not stromal, cells exhibit advanced disease stage (middle panels) and increased lymph 
node tumor burden (right panels).  N categories and disease stage scores are specified in 
Table II and are based on the AJCC/TNM system.
19
  ↑MMP-9, MMP-9 overexpression; 
↓MMP-9, MMP-9 downregulation.  Values in middle and right panels are means ± SEM.  
*, p<0.05 by the Wilcoxon two-sample test. 
Figure 4.  Overexpression of tumor epithelial cell MMP-9 in metastatic colorectal 
cancer is detected by immunostaining.  IHC (left panels) and immunofluorescence 
(right panels) analyses of primary tumors (Tumor) and matched normal adjacent tissues 
(NAT) from colorectal cancer patients with metastatic disease progression.  For IHC 
(magnification, 40X), tissues were stained with specific goat polyclonal anti-MMP-9 
(brown) and hematoxylin (blue, nuclei).  For immunofluorescence, tissues were stained 
with DAPI (blue, nuclei) and specific antibodies against MMP-9 (red) and the epithelial-
specific marker β-catenin (green), and subjected to confocal microscopy (magnification, 
100X). 
 
T84 cells were treated in vitro for 24 hours in serum free 
DMEM/F12 media with PBS, 1 ìM ST, 5 mM 8-bromo-cGMP 
or 1 mM 8-pCPT-cGMP. Conditioned media was collected 
and subjected to immunoblot analysis (A) or gelatin 
zymography (B).  Treatment with ST or a cell permeable 
cGMP analogue resulted in a decrease of MMP-9 protein (A), 
and reduced MMP-9 activity detected in conditioned media 
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